Mesoblast (NASDAQ:MESO) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $18.19 and traded as low as $16.50. Mesoblast shares last traded at $16.67, with a volume of 144,397 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Mesoblast currently has a consensus rating of “Moderate Buy”.

Mesoblast Stock Performance

The company has a quick ratio of 1.77, a current ratio of 1.99 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average of $18.15 and a 200 day moving average of $16.82. The stock has a market capitalization of $2.17 billion, a P/E ratio of -19.15 and a beta of 2.15.

Institutional Trading of Mesoblast

Several institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new position in Mesoblast during the fourth quarter worth $34,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Mesoblast by 30.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after purchasing an additional 558 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Mesoblast by 55.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,012 shares in the last quarter. JFS Wealth Advisors LLC bought a new position in Mesoblast during the 3rd quarter valued at about $54,000. Finally, Farther Finance Advisors LLC acquired a new position in Mesoblast in the third quarter valued at about $58,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.